Publications by authors named "Maria Paris"

Claim this Profile
E
Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.
Loretta Fiorillo, Emily Becker, Raul de Lucas, Anna Belloni-Fortina, Susana Armesto, Maria Paris

J Am Acad Dermatol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.
Joseph F Merola, Lawrence Charles Parish, Lyn Guenther, Charles Lynde, Jean-Philippe Lacour, Maria Paris

J Am Acad Dermatol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Shigetoshi Sano, Akimichi Morita, Maria Paris

Am J Clin Dermatol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Shigetoshi Sano, Akimichi Morita, Maria Paris

Am J Clin Dermatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet's Syndrome.
Philip J Mease, Gülen Hatemi, Maria Paris, Sue Cheng, Peter Maes

Am J Clin Dermatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
Ulrich Mrowietz, Jonathan Barker, Curdin Conrad, Denis Jullien, Paolo Gisondi, Maria Paris

J Eur Acad Dermatol Venereol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink.
Rebecca Persson, Myriam Cordey, Maria Paris, Susan Jick

Drug Saf· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
Gülen Hatemi, Alfred Mahr, Mitsuhiro Takeno, Doyoung Kim, Melike Melikoğlu, Maria Paris

RMD Open· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study.
Yukari Okubo, Hidetoshi Takahashi, Ryosuke Hino, Koki Endo, Satoru Kikuchi, Maria Paris

Dermatol Ther (Heidelb)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
Alvin F Wells, Christopher J Edwards, Alan J Kivitz, Paul Bird, Benoit Guerette, Maria Paris

Rheumatology (Oxford)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study.
Mitsuhiro Takeno, Hiroaki Dobashi, Yoshiya Tanaka, Hajime Kono, Shouji Sugii, Maria Paris

Mod Rheumatol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
Linda Stein Gold, Kim Papp, David Pariser, Lawrence Green, Neal Bhatia, Maria Paris

J Am Acad Dermatol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4.
Teresa Wegesser, Aldo Coppi, Tod Harper, Maria Paris, Sheroy Minocherhomji

Regul Toxicol Pharmacol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.
Gülen Hatemi, Alfred Mahr, Mitsuhiro Takeno, Do Young Kim, David Saadoun, Maria Paris

Clin Exp Rheumatol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry.
Alice B Gottlieb, Joseph F Merola, Joshua Cirulli, Catherine C Williams, Gregory J Linowski, Maria Paris

Dermatol Ther (Heidelb)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials.
Philip J Mease, Dafna D Gladman, Juan J Gomez-Reino, Stephen Hall, Arthur Kavanaugh, Maria Paris

ACR Open Rheumatol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
Abby S Van Voorhees, Linda Stein Gold, Mark Lebwohl, Bruce Strober, Charles Lynde, Maria Paris

J Am Acad Dermatol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
Amy S Paller, Ying Hong, Emily M Becker, Raul de Lucas, Maria Paris

J Am Acad Dermatol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis.
Katrina Wilcox Hagberg, Rebecca Persson, Catherine Vasilakis-Scaramozza, Steve Niemcryk, Michael Peng, Maria Paris

Clin Epidemiol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
Gülen Hatemi, Alfred Mahr, Yoshiaki Ishigatsubo, Yeong-Wook Song, Mitsuhiro Takeno, Maria Paris

N Engl J Med· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
Arthur Kavanaugh, Dafna D Gladman, Christopher J Edwards, Georg Schett, Benoit Guerette, Maria Paris

Arthritis Res Ther· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial.
Alvin F Wells, Christopher J Edwards, Alan J Kivitz, Paul Bird, Dianne Nguyen, Maria Paris

Rheumatology (Oxford)· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world burden of comorbidities in US patients with psoriatic arthritis.
Kamal Shah, Maria Paris, Lillian Mellars, Arun Changolkar, Philip J Mease

RMD Open· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rates of Cancers and Opportunistic Infections in Patients With Psoriatic Arthritis Compared With Patients Without Psoriatic Arthritis.
Katrina Wilcox Hagberg, Lin Li, Michael Peng, Maria Paris, Kamal Shah

J Clin Rheumatol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis